Remember meForgot password?
    Log in with Twitter

article imageScientists studying the effects of high-dose vitamin C on non-Hodgkin lymphoma

By ashley.woods4     Jan 4, 2008 in Health
Researchers have received approval for a first-of-its kind study to determine whether high doses of vitamin C will slow the spread of non-Hodgkin's lymphoma.
Twenty non-Hodgkin's lymphoma patients from Thomas Jefferson University Hospital and Jefferson's Kimmel Cancer Center will begin enrollment in the study within the next few weeks.
These patients have all failed the standard therapy for their conditions.
During the study each patient will be given varied intravenous doses of vitamin C three times a week, which is expected to last four to six weeks.
Dr. Daniel Monti, director of Jefferson's Myrna Brind Center of Integrative Medicine and study's lead investigator notes that when vitamin C is taken orally there is only so much that the body can absorb. The rest of the vitamin C is left for the body to dispose of. However, intravenous dosing can allow the body to absorb 70 times the amount of vitamin C.
According to a press release, "Recent research conducted by the NIH collaborators of this study has shown that when given in sufficient amounts intravenously, vitamin C converts to hydrogen peroxide. When applied to certain non-Hodgkin lymphoma cells in the laboratory, the converted hydrogen peroxide kills them while leaving the surrounding healthy cells intact."
Monti said in the press release:''It is these high blood levels that are required to get the mechanism of action, vitamin C converting to hydrogen peroxide around the cancer cells, to occur."Dr. Monti says earlier studies have found that high doses of vitamin C generates hydrogen peroxide which can selectively kill some cancer cells while leaving normal cells alone.
Other benefits of using vitamin C in cancer therapy are the low costs as well as the low toxicity.
More about Vitamin, Cancer, Cure
Latest News
Top News